Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.48 |
| ▸ | ABL1 | P00519 | 12/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4840565 | 1.00 | NPC1 (0.51) | NPC1RAB9ATRPV1ABL1KCNH2 | |
| SCHEMBL4846819 | 0.93 | TRPV1 (0.46) | NPC1RAB9ATRPV1 | |
| SCHEMBL4846828 | 0.93 | TRPV1 (0.46) | NPC1RAB9ATRPV1 | |
| SCHEMBL4839109 | 0.93 | RAB9A (0.49) | NPC1RAB9A | |
| SCHEMBL4839102 | 0.93 | RAB9A (0.49) | NPC1RAB9A | |
| SCHEMBL4841961 | 0.93 | RAB9A (0.49) | NPC1RAB9AABL1 | |
| SCHEMBL4841947 | 0.93 | RAB9A (0.49) | NPC1RAB9AABL1 | |
| SCHEMBL4844437 | 0.92 | KMT2A (0.47) | NPC1RAB9A | |
| SCHEMBL4844449 | 0.92 | KMT2A (0.47) | NPC1RAB9A | |
| SCHEMBL4839934 | 0.92 | NPC1 (0.57) | NPC1RAB9ATRPV1ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7378428-B2 | Nitrogen-containing bicyclic compounds and drugs containing the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-05-27 | — | — | US | disclosed |
| US-20050222138-A1 | Nitrogen-containing bicyclic compounds and drugs containing the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222138-A1 | Nitrogen-containing bicyclic compounds and drugs containing the same as the active ingredient | PARK7, MMP8, CDK7 | NPC1 985/4885RAB9A 2220/4885TRPV1 1672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.